Efforts are under way to define the role of minimally invasive strategies for molecular monitoring and risk stratification in endometrial cancer. A recent publication aims to define the association between circulating tumor DNA level and disease stage in patients with newly diagnosed endometrial cancer and determine whether sequencing of longitudinal cell-free DNA samples can be used for disease monitoring and detection of progression or recurrence. These results accelerate the current knowledge of molecular follow-up in endometrial cancer.
Molecular Monitoring in Endometrial Cancer—Ready for Prime Time?
Clin Cancer Res 2023;29:305–8
- Views Icon Views
- Share Icon Share
- Search Site
- Article Versions Icon Versions
Brooke M. Grant, Trevor J. Pugh, Amit M. Oza; Molecular Monitoring in Endometrial Cancer—Ready for Prime Time?. Clin Cancer Res 15 January 2023; 29 (2): 305–308. https://doi.org/10.1158/1078-0432.CCR-22-2781
Download citation file:
Sign in via your InstitutionSign in via your Institution
Citing articles via